Clinical trials: Gastrointestinal Stromal Tumor (GIST)
Gastrointestinal Stromal Tumors
A Cohort Study on the Safety of Laparoscopic Resection of 5cm or Larger Gastric Gastrointestinal Stromal Tumors
The purpose of this study is to explore the safety of laparoscopic resection of 5cm or larger gastric gastrointestinal stromal tumors
- Trial name
- NCT05938309
- Where
- China
- Volunteers
- 194 people
- Sponsor
- Fujian Medical University
Sarcoma
PTK787/ZK222584 in the Treatment of Metastatic Gastrointestinal Stromal Tumors Resistant to Imatinib
This study evaluates the safety and efficacy of a novel tyrosine kinase inhibitor, PTK787/ZK222584, in the treatment of GIST (gastrointestinal stromal tumor) that is resistant to imatinib mesylate (Gleevec).
- Trial name
- NCT00117299
- Testing
- PTK787/ZK222584
- Where
- Finland
- Volunteers
- 45 people
- Sponsor
- University of Helsinki
Paraganglioma/ Phaeochromocytoma, Melanoma and Other Malignant Neoplasms of Skin
An International Study on Pediatric Patients With Rare Tumors.
The PARTNER study is an international, prospective, observational study of paediatric patients with very rare tumours.
- Conditions
- Paraganglioma/ Phaeochromocytoma, Melanoma and Other Malignant Neoplasms of Skin, Gastrointestinal Stromal Tumor (GIST), Adrenocortical Tumor
- Trial name
- PARTNER (NCT07072143)
- Where
- Italy
- Volunteers
- 6,250 people
- Sponsor
- Azienda Ospedaliera di Padova
Gastrointestinal Stromal Tumor, Sarcoma
Brostallicin in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of brostallicin in treating patients who have locally…
- Trial name
- NCT00041249
- Testing
- brostallicin
- Where
- 16 sites in Belgium, France and 3 more
- Volunteers
- 64 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Melanoma, Non-small Cell Lung Cancer
A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors
The goal of this clinical research study is to learn how PLX3397 and pembrolizumab work together to affect cancer cells. PLX3397 is designed to target the receptor for CSF1 (CSF1R).
- Conditions
- Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Gastrointestinal Stromal Tumor (GIST)
- Trial name
- NCT02452424
- Testing
- PLX3397, Pembrolizumab
- Where
- 12 sites in United States
- Volunteers
- 78 people
- Sponsor
- Daiichi Sankyo
Gastrointestinal Stromal Tumors
PDR001 Plus Imatinib for Metastatic or Unresectable GIST
Assuming that PDR001, an anti-PD-1 antibody, with imatinib might be effective in advanced GIST after failure of standard TKI therapies including imatinib, sunitinib, and regorafenib.
- Trial name
- NCT03609424
- Testing
- PDR001, Imatinib
- Where
- South Korea
- Volunteers
- 39 people
- Sponsor
- Asan Medical Center
Gastrointestinal Stromal Tumors
Single Agent Regorafenib in First-line for Metastatic/Unresectable KIT/PDGFR Wild Type GIST
Evaluate the treatment with regorafenib in patients with metastatic and/or unresectable KIT/PDGFR wild type GIST in the first line setting.
- Trial name
- REGISTRI (NCT02638766)
- Testing
- regorafenib
- Where
- 17 sites in France, Italy and 1 more
- Volunteers
- 15 people
- Sponsor
- Grupo Espanol de Investigacion en Sarcomas
Gastrointestinal Stromal Neoplasms
A Study to Investigate Velzatinib Compared With Imatinib in Adult Participants With Previously Untreated Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (StrateGIST Frontline)
Gastrointestinal Stromal Tumour (GIST) is a soft tissue tumour that develops in the digestive system, most often in the stomach or small intestine.
- Trial name
- NCT07585266
- Testing
- Velzatinib, Imatinib
- Where
- 93 sites in United States, Argentina and 18 more
- Volunteers
- 800 people
- Sponsor
- GlaxoSmithKline
Advanced Gastrointestinal Stromal Tumor
Evaluate the Efficacy of AMG 706 to Treat Advanced Gastrointestinal Stromal Tumors
The purpose of the study is to evaluate the safety and efficacy of AMG 706 in patients with gastrointestinal stromal tumor that have not been controlled while taking imatinib mesylate.
- Trial name
- NCT00254267
- Testing
- AMG 706
- Volunteers
- 35 people
- Sponsor
- Amgen
Gastrointestinal Stromal Tumor (GIST)
Pazopanib in Imatinib Refractory or Intolerant Gastrointestinal Stromal Tumors (GIST)
This study is being done to gather information about the safety (any harmful effects) and effectiveness (usefulness) of Pazopanib in the treatment of Gastrointestinal Stroma Tumors (GIST) that cannot be treated by surgery or has…
- Trial name
- NCT01391611
- Testing
- Pazopanib
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Kristen Ganjoo
Gastric Cancer, Gastric Neoplasm
Surgery in Gastrointestinal Stromal Tumors (GISTs) for Treatment, Tumor Modeling, and Genomic Analysis
Objective: To follow people with GISTs and collect tumor tissue so that it can be studied in the lab. Eligibility: People age 6 and older who have a GIST.
- Conditions
- Gastric Cancer, Gastric Neoplasm, Gastrointestinal Stromal Sarcoma, Gastrointestinal Stromal Neoplasm
- Trial name
- NCT04557969
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- National Cancer Institute (NCI)
Gastrointestinal Stromal Tumor, Recurrent Adult Soft Tissue Sarcoma
Doxorubicin Hydrochloride and Alvocidib in Treating Patients With Metastatic or Recurrent Sarcoma That Cannot Be Removed By Surgery
This phase I trial is studying the side effects and best dose of alvocidib when given with doxorubicin hydrochloride in treating patients with metastatic or recurrent sarcoma that cannot be removed by surgery.
- Conditions
- Gastrointestinal Stromal Tumor, Recurrent Adult Soft Tissue Sarcoma, Stage IV Adult Soft Tissue Sarcoma
- Trial name
- NCT00098579
- Testing
- alvocidib, doxorubicin hydrochloride
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- National Cancer Institute (NCI)
Carney Complex, Chondrosarcoma
Linsitinib in Treating Patients With Gastrointestinal Stromal Tumors
This phase II trial studies how well linsitinib works in treating younger and adult patients with gastrointestinal stromal tumors.
- Conditions
- Carney Complex, Chondrosarcoma, Gastrointestinal Stromal Tumor, Paraganglioma
- Trial name
- NCT01560260
- Testing
- Laboratory Biomarker Analysis, Linsitinib, Pharmacological Study
- Where
- 8 sites in United States
- Volunteers
- 20 people
- Sponsor
- National Cancer Institute (NCI)
Gastrointestinal Stromal Tumors
WB-DWI for Early Prediction of Therapy Response in Patients With Advanced Metastatic GIST Treated With Regorafenib
The purpose of this study is to evaluate WB DWI as early predictor of response to treatment with regorafenib or placebo in patients with advanced metastatic GIST.
- Trial name
- NCT01265979
- Testing
- Whole body diffusion MRI
- Where
- Belgium
- Volunteers
- 5 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
GIST With D842V Mutated PDGFRA Gene
Randomized Trial of Crenolanib in Subjects With D842V Mutated GIST
This is a multicenter, randomized, double-blinded, placebo-controlled, trial of oral crenolanib versus oral placebo in combination with best supportive care in subjects with advanced or metastatic GIST with a D842V mutation in…
- Trial name
- NCT02847429
- Testing
- Crenolanib
- Where
- 23 sites in United States, France and 5 more
- Volunteers
- 120 people
- Sponsor
- Arog Pharmaceuticals, Inc.
Gastrointestinal Stromal Tumor (GIST)
A Study to Investigate the Safety and Efficacy of AT13387, Alone or in Combination With Imatinib, in Patients With GIST
The purpose of this study is to investigate if an investigational drug called AT13387 is active against Gastrointestinal Stromal Tumor (GIST) that is resistant to other treatments, and to understand more about the safety of…
- Trial name
- NCT01294202
- Testing
- AT13387 and Imatinib
- Where
- 8 sites in United States
- Volunteers
- 26 people
- Sponsor
- Astex Pharmaceuticals, Inc.
Cancer
Early Intervention vs. Standard Palliative Care in Improving End-of-Life Care in Advanced Cancer Patients
RATIONALE: Palliative care may help patients with advanced cancer live more comfortably. PURPOSE: This randomized clinical trial is studying an early intervention palliative care program to see how well it works compared to a…
- Trial name
- NCT00253383
- Testing
- counseling intervention, educational intervention, psychosocial assessment and care
- Where
- 2 sites in United States
- Volunteers
- 329 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Colorectal Neoplasms, Gastrointestinal Stromal Tumors
The Effects of the Proton Pump Inhibitor Esomeprazole on the Bioavailability of Regorafenib
Regorafenib is a novel oral multi-kinase inhibitor which targets angiogenic, stromal and oncogenic receptor tyrosine kinases. It is currently registered for GIST and mCRC.
- Trial name
- REGORA (NCT02800330)
- Testing
- Esomeprazole 40mg concomitantly, Esomeprazole 40mg before, Regorafenib 160mg or 120mg
- Where
- Netherlands
- Volunteers
- 31 people
- Sponsor
- Erasmus Medical Center
Non Small Cell Lung Cancer, Gastrointestinal Stromal Tumor (GIST)
Clinical Utility of ctDNA in Detecting Resistance Mechanisms and Delivering Precision Medicine to Cancer Patients
ctDNA stands for circulating tumour DNA. As ctDNA is released by tumour cells into the blood stream, taking a blood sample and analysing it for ctDNA, can provide a lot of useful information about a patient's cancer.
- Conditions
- Non Small Cell Lung Cancer, Gastrointestinal Stromal Tumor (GIST), Colorectal Cancer, Biliary Tract Cancer
- Trial name
- CURTAIN (NCT07673861)
- Testing
- Marsden360 ctDNA test and GTAB review
- Where
- United Kingdom
- Volunteers
- 100 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Hypereosinophilic Syndrome, Systemic Mastocytosis
Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase Enzymes
This trial is for various types of malignancies which may depend on certain enzymes (tyrosine kinases) for growth. The objective of this study is to assess to what extent imatinib mesylate blocks these enzymes and to assess the…
- Conditions
- Hypereosinophilic Syndrome, Systemic Mastocytosis, Chronic Myelomonocytic Leukemia, Dermatofibrosarcoma
- Trial name
- NCT00171912
- Testing
- imatinib mesylate
- Where
- Australia
- Volunteers
- 38 people
- Sponsor
- Novartis Pharmaceuticals